About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- Don't condemn globalization, it's not all about the West: WEF's Schwab
- Protectionism is good for no-one: Brazil finance minister
- The world’s eight richest people have same amount of money as half the world: Oxfam
- Trump’s protectionism does not worry China’s Asian Infrastructure Investment Bank
- Singapore central bank chief: City-state’s property market stabilizing
NBR on TwitterMy Tweets
Subscribe to RSS
Given a choice between health and money in retirement, young women will go for the big bucks, according to research from Schwab.
Retirees will pay more for this medical insurance program in the new year. Find out how much you’ll pay.
The health-care industry is shifting $100B toward tech, which has big implications for Americans seeking new jobs or transitioning careers.
It’s finally time to choose your workplace benefits and health-care insurance for 2017. Here’s how to make sure you pick the right plan.
Last year the flu cost the economy billions of dollars. This season could be worse, since fewer people are opting for vaccinations.
The sign-ups would represent a modest increase in enrollment over 2016.
A new drug being tested slows Alzheimer’s by removing plaque buildup in the brain. It’s hope for millions suffering from the disease.
Shopping around for better coverage can cut your monthly premiums and out-of-pocket expenses by hundreds of dollars next year.
Researchers are working on opioids with all the painkilling power of current drugs but with less risk of addiction or overdose.
Mylan soared Monday after it agreed to pay $465 million to settle charges that it overcharged the government for its EpiPen products.
Meg Tirrell reports on claims that Mylan misclassified the EpiPen in order to pay smaller discounts to states.
Goldman Sachs forecasts the health-care sector could see a particularly rocky upcoming few months.
Mylan also faces heat from multiple regulatory and legal agencies over huge cost increases for the anti-allergy auto-injectors.
Mylan CEO Heather Bresch is set to testify Wednesday before a House committee over sky-high price hikes for lifesaving EpiPens.
Despite rising Obamacare prices, the total premiums paid in many cases are less than work-based coverage.